BACKGROUND: Plasmodium falciparum malaria is a pressing global health problem. A previous study of the malaria vaccine RTS,S (which targets the circumsporozoite protein), given with an adjuvant system (AS02A), showed a 30% rate of protection against clinical malaria in children 1 to 4 years of age. We evaluated the efficacy of RTS,S given with a more immunogenic adjuvant system (AS01E) in children 5 to 17 months of age, a target population for vaccine licensure. METHODS: We conducted a double-blind, randomized trial of RTS,S/AS01E vaccine as compared with rabies vaccine in children in Kilifi, Kenya, and Korogwe, Tanzania. The primary end point was fever with a falciparum parasitemia density of more than 2500 parasites per microliter, and the mean duration of follow-up was 7.9 months (range, 4.5 to 10.5). RESULTS: A total of 894 children were randomly assigned to receive the RTS,S/AS01E vaccine or the control (rabies) vaccine. Among the 809 children who completed the study procedures according to the protocol, the cumulative number in whom clinical malaria developed was 32 of 402 assigned to receive RTS,S/AS01E and 66 of 407 assigned to receive the rabies vaccine; the adjusted efficacy rate for RTS,S/AS01E was 53% (95% confidence interval [CI], 28 to 69; P<0.001) on the basis of Cox regression. Overall, there were 38 episodes of clinical malaria among recipients of RTS,S/AS01E, as compared with 86 episodes among recipients of the rabies vaccine, with an adjusted rate of efficacy against all malarial episodes of 56% (95% CI, 31 to 72; P<0.001). All 894 children were included in the intention-to-treat analysis, which showed an unadjusted efficacy rate of 49% (95% CI, 26 to 65; P<0.001). There were fewer serious adverse events among recipients of RTS,S/AS01E, and this reduction was not only due to a difference in the number of admissions directly attributable to malaria. CONCLUSIONS: RTS,S/AS01E shows promise as a candidate malaria vaccine. (ClinicalTrials.gov number, NCT00380393.) 2008 Massachusetts Medical Society
RCT Entities:
BACKGROUND:Plasmodium falciparummalaria is a pressing global health problem. A previous study of the malaria vaccine RTS,S (which targets the circumsporozoite protein), given with an adjuvant system (AS02A), showed a 30% rate of protection against clinical malaria in children 1 to 4 years of age. We evaluated the efficacy of RTS,S given with a more immunogenic adjuvant system (AS01E) in children 5 to 17 months of age, a target population for vaccine licensure. METHODS: We conducted a double-blind, randomized trial of RTS,S/AS01E vaccine as compared with rabies vaccine in children in Kilifi, Kenya, and Korogwe, Tanzania. The primary end point was fever with a falciparum parasitemia density of more than 2500 parasites per microliter, and the mean duration of follow-up was 7.9 months (range, 4.5 to 10.5). RESULTS: A total of 894 children were randomly assigned to receive the RTS,S/AS01E vaccine or the control (rabies) vaccine. Among the 809 children who completed the study procedures according to the protocol, the cumulative number in whom clinical malaria developed was 32 of 402 assigned to receive RTS,S/AS01E and 66 of 407 assigned to receive the rabies vaccine; the adjusted efficacy rate for RTS,S/AS01E was 53% (95% confidence interval [CI], 28 to 69; P<0.001) on the basis of Cox regression. Overall, there were 38 episodes of clinical malaria among recipients of RTS,S/AS01E, as compared with 86 episodes among recipients of the rabies vaccine, with an adjusted rate of efficacy against all malarial episodes of 56% (95% CI, 31 to 72; P<0.001). All 894 children were included in the intention-to-treat analysis, which showed an unadjusted efficacy rate of 49% (95% CI, 26 to 65; P<0.001). There were fewer serious adverse events among recipients of RTS,S/AS01E, and this reduction was not only due to a difference in the number of admissions directly attributable to malaria. CONCLUSIONS: RTS,S/AS01E shows promise as a candidate malaria vaccine. (ClinicalTrials.gov number, NCT00380393.) 2008 Massachusetts Medical Society
Authors: Alice M Nyakeriga; Marita Troye-Blomberg; Alex K Chemtai; Kevin Marsh; Thomas N Williams Journal: Am J Clin Nutr Date: 2004-12 Impact factor: 7.045
Authors: C G Nevill; E S Some; V O Mung'ala; W Mutemi; L New; K Marsh; C Lengeler; R W Snow Journal: Trop Med Int Health Date: 1996-04 Impact factor: 2.622
Authors: William H H Reece; Margaret Pinder; Philip K Gothard; Paul Milligan; Kalifa Bojang; Tom Doherty; Magdalena Plebanski; Peter Akinwunmi; Simone Everaere; Katherine R Watkins; Gerald Voss; Nadia Tornieporth; Ali Alloueche; Brian M Greenwood; Kent E Kester; Keith P W J McAdam; Joe Cohen; Adrian V S Hill Journal: Nat Med Date: 2004-03-14 Impact factor: 53.440
Authors: Brenda A Okech; Patrick H Corran; James Todd; Amy Joynson-Hicks; Chairat Uthaipibull; Thomas G Egwang; Anthony A Holder; Eleanor M Riley Journal: Infect Immun Date: 2004-03 Impact factor: 3.441
Authors: Keith Z Hazleton; Meng-Chiao Ho; Maria B Cassera; Keith Clinch; Douglas R Crump; Irving Rosario; Emilio F Merino; Steve C Almo; Peter C Tyler; Vern L Schramm Journal: Chem Biol Date: 2012-06-22
Authors: Karen S Harris; Christopher G Adda; Madhavi Khore; Damien R Drew; Antonina Valentini-Gatt; Freya J I Fowkes; James G Beeson; Sheetij Dutta; Robin F Anders; Michael Foley Journal: Infect Immun Date: 2014-08-25 Impact factor: 3.441
Authors: Mark A Pierce; Ruth D Ellis; Laura B Martin; Elissa Malkin; Eveline Tierney; Kazutoyo Miura; Michael P Fay; Joanne Marjason; Suzanne L Elliott; Gregory E D Mullen; Kelly Rausch; Daming Zhu; Carole A Long; Louis H Miller Journal: Vaccine Date: 2010-01-04 Impact factor: 3.641